A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States

Completed · Phase 3

Conditions studied: Systemic Lupus Erythematosus

In brief

This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.

Key facts

Study ID

NCT00724867

Run by

Human Genome Sciences Inc., a GSK Company

People needed

268

Starts

2008-08-01

Expected to finish

2015-03-01

Last updated by the study team

2016-03-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.
• Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.

You may not qualify if…

• Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.

Where it is running

• GSK Investigational Site — Phoenix, Arizona, United States
• GSK Investigational Site — Tucson, Arizona, United States
• GSK Investigational Site — Long Beach, California, United States
• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Los Angeles, California, United States
• GSK Investigational Site — Upland, California, United States
• GSK Investigational Site — Washington D.C., District of Columbia, United States
• GSK Investigational Site — Aventura, Florida, United States
• GSK Investigational Site — Orlando, Florida, United States
• GSK Investigational Site — Tampa, Florida, United States
• GSK Investigational Site — Atlanta, Georgia, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Chicago, Illinois, United States
• GSK Investigational Site — Munster, Indiana, United States
• GSK Investigational Site — Kansas City, Kansas, United States
• GSK Investigational Site — Louisville, Kentucky, United States
• GSK Investigational Site — Baton Rouge, Louisiana, United States
• GSK Investigational Site — Baltimore, Maryland, United States
• GSK Investigational Site — Cumberland, Maryland, United States
• GSK Investigational Site — Hagerstown, Maryland, United States
• GSK Investigational Site — Ann Arbor, Michigan, United States
• GSK Investigational Site — Lansing, Michigan, United States
• GSK Investigational Site — Brooklyn, New York, United States
• GSK Investigational Site — Great Neck, New York, United States
• GSK Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.